Table 5.
Comparison of immune cell infiltration in the DCIS and invasive components of individual tumors
| Hormone receptor status | Immune cell subset | Invasive component | DCIS component | Invasive > DCIS No. of cases |
Invasive < DCIS No. of cases |
Invasive = DCIS No. of cases |
p value |
|---|---|---|---|---|---|---|---|
| All (n = 90) | CD4+ TIL | 79.5 (42.0–198.5) | 38.5 (12.0–101.8) | 69 | 26 | 0 | < 0.001 |
| CD8+ TIL | 58.5 (26.8–144.3) | 18.0 (5.5–44.3) | 71 | 18 | 1 | < 0.001 | |
| FOXP3+ TIL | 4.0 (1.0–12.3) | 1.0 (0.0–3.3) | 56 | 16 | 18 | < 0.001 | |
| PD-L1+ IC | 35 (38.9) | 19 (21.1) | 16a | 0b | 19c/55d | < 0.001 | |
| Positive (n = 67) | CD4+ TIL | 73.0 (26.0–195.0) | 18.0 (10.0–65.0) | 49 | 18 | 0 | < 0.001 |
| CD8+ TIL | 45.0 (20.0–100.0) | 11.0 (3.0–33.0) | 53 | 13 | 1 | < 0.001 | |
| FOXP3+ TIL | 2.0 (0.0–8.0) | 1.0 (0.1–2.0) | 41 | 8 | 18 | < 0.001 | |
| PD-L1+ IC | 19 (28.4) | 9 (13.4) | 10a | 0b | 9c/48d | 0.002 | |
| Negative (n = 23) | CD4+ TIL | 124.0 (70.0–220.0) | 101.0 (53.0–185.0) | 15 | 8 | 0 | 0.584 |
| CD8+ TIL | 143.0 (84.0–274.0) | 45.0 (23.0–81.0) | 18 | 5 | 0 | 0.004 | |
| FOXP3+ TIL | 10.0 (2.0–13.0) | 4.0 (1.0–6.0) | 15 | 8 | 0 | 0.022 | |
| PD-L1+ IC | 16 (69.6) | 10 (43.5) | 6a | 0b | 10c/7d | 0.031 |
p values were calculated by the Wilcoxon signed rank test or McNemar test
Data are presented as median (interquartile range) for CD4+, CD8+, and FOXP3+ TILs and as number of positive cases (%) for PD-L1 IC
aInvasive (+)/DCIS (−); binvasive (−)/DCIS (+); cinvasive (+)/DCIS (+); dinvasive (−)/DCIS (−)
TIL tumor-infiltrating lymphocyte, IC immune cell, DCIS ductal carcinoma in situ